GW-501516 (Cardarine) Capsules

Buy GW-501516 (Cardarine) Capsules Online

Buy GW-501516 (Cardarine) Capsules are research-grade compounds designed for scientific studies, particularly in the field of nuclear receptor pharmacology. GW-501516 is a potent and selective agonist of the peroxisome proliferator-activated receptor delta (PPARδ), a nuclear receptor involved in the regulation of lipid metabolism and energy homeostasis.

Chemical Structure and Physical Properties

• Chemical Name: 2-[2-[4-(Trifluoromethyl)phenyl]thiazol-4-yl]acetic acid
• Synonyms: GW501516, Cardarine
• Molecular Formula: C₂₁H₁₈F₃NO₃S₂
• Molecular Weight: 453.5 g/mol
• CAS Number: 317318-70-0
• Form: Capsules containing GW-501516 in a suitable excipient
• Appearance: Capsules with off-white to pale yellow powder
• Purity: ≥98%
• Solubility: Soluble in organic solvents such as DMSO (20 mg/mL) and ethanol (12 mg/mL); insoluble in water
• Storage Recommendations: Store at -20°C to maintain stability

Intended Use

GW-501516 Capsules are intended strictly for laboratory research and analytical purposes. Researchers utilize this compound to study its pharmacodynamics, receptor binding affinities, and potential applications within the PPARδ agonist class. This product is not intended for human or animal consumption.

Packaging and Shipping

• Packaging: Each capsule is securely packaged to maintain product integrity and confidentiality.
• Shipping: Orders are shipped discreetly with tracking provided. Delivery times vary depending on the destination and the supplier’s shipping policies.

Legal and Compliance Disclaimer

• Research Use Only: GW-501516 Capsules are sold strictly for laboratory research and analytical purposes.
• Legal Status: The legal status of GW-501516 varies by jurisdiction. Customers are responsible for verifying the legal status in their respective countries before ordering.
• Age Restriction: Purchasers must be 18 years or older.
• Safety Compliance: Appropriate laboratory personal protective equipment (PPE) should be used when handling this compound. Avoid direct skin contact and inhalation. Store in a cool, dry place away from direct sunlight.

Hazard Statements

• Hazard Symbols: ⚠️
• Hazard Statements:
  • H351: Suspected of causing cancer.
• Precautionary Statements:
  • P201: Obtain special instructions before use.
  • P202: Do not handle until all safety precautions have been read and understood.
  • P280: Wear protective gloves/protective clothing/eye protection/face protection.
  • P308 + P313: IF exposed or concerned: Get medical advice/attention.
  • P405: Store locked up.
  • P501: Dispose of contents/container to an approved waste disposal plant.

Development and History

GW-501516 was initially discovered during a research collaboration between GlaxoSmithKline (GSK) and Ligand Pharmaceuticals that began in 1992. The compound was developed as a metabolic activator targeting PPARδ, with potential applications in treating obesity, diabetes, lipid disorders, and cardiovascular diseases. Phase I trials for hyperlipidemia began in 2000, followed by Phase I/II in 2002. By 2007, GW-501516 had completed two Phase II clinical studies, but GSK abandoned further development of the drug in 2007 for undisclosed reasons.

Ordering Information

GW-501516 Capsules are available for purchase through various research chemical suppliers. Ensure that you are ordering from a reputable source that complies with all legal and safety regulations. Before placing an order, verify the legal status of GW-501516 in your jurisdiction and ensure that you meet all necessary requirements for purchasing research chemicals.

Please note that this product is not intended for human or animal consumption and should only be handled by qualified professionals in a controlled laboratory setting.